We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

39 hedge funds and large institutions have $8.24M invested in BRAINSTORM CELL THERAPUTC in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

8% more capital invested

Capital invested by funds: $7.61M → $8.24M (+$628K)

5% more funds holding

Funds holding: 37 → 39 (+2)

0.03% more ownership

Funds ownership: 0.59% → 0.63% (+0.03%)

95% less call options, than puts

Call options by funds: $107K | Put options by funds: $2.22M

Holders
39
Holders Change
+2
Holders Change %
+5.41%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
10
Reduced
5
Closed
3
Calls
$107K
Puts
$2.22M
Net Calls
-$2.11M
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
RJA
Raymond James & Associates
Florida
+$341K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$295K
3
WG
Winton Group
United Kingdom
+$295K
4
Renaissance Technologies
Renaissance Technologies
New York
+$286K
5
EMG
ETF Managers Group
New Jersey
+$103K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$622K
2
Citadel Advisors
Citadel Advisors
Florida
-$66K
3
Wolverine Trading
Wolverine Trading
Illinois
-$65.8K
4
Simplex Trading
Simplex Trading
Illinois
-$62.8K
5
IWM
IHT Wealth Management
Illinois
-$16.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$20K -$531 -9 -3%
First Manhattan
27
First Manhattan
New York
$15K +$2K +34 +15%
Citigroup
28
Citigroup
New York
$12K +$10.9K +184 +1,415%
Fidelity Investments
29
Fidelity Investments
Massachusetts
$11K +$10.9K +184 New
UBS Group
30
UBS Group
Switzerland
$10K -$10.1K -171 -51%
SPIA
31
Steward Partners Investment Advisory
New York
$9K – – –
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
$8K – – –
IFAM
33
Institutional & Family Asset Management
Colorado
$8K – – –
ASN
34
Advisory Services Network
Georgia
$2K – – –
VFA
35
Valeo Financial Advisors
Indiana
$2K – – –
TRCT
36
Tower Research Capital (TRC)
New York
$2K +$2.54K +43 New
KFS
37
Kelly Financial Services
Massachusetts
$1.3K – – –
US Bancorp
38
US Bancorp
Minnesota
$1K – – –
SM
39
Sabby Management
Florida
– -$622K -10,543 Closed
Citadel Advisors
40
Citadel Advisors
Florida
– -$66K -1,121 Closed
Simplex Trading
41
Simplex Trading
Illinois
– -$62.8K -1,065 Closed
1
2

BCLI Hedge Fund Activity: Q3 2019 in Review

39 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2019, worth a combined $8.24M — up 8.3% from $7.61M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BCLI positions and 3 closed out — a net gain of 3 holders — while 10 added to existing stakes and 5 trimmed.

The largest buyer was Raymond James & Associates, opening a new position worth an estimated $341K. The largest seller was Sabby Management, exiting entirely with an estimated $622K sold.

  • 39 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2019, up from 37 in Q2 2019.
  • Funds reported $8.24M of BRAINSTORM CELL THERAPUTC stock for Q3 2019, up 8.3% quarter-over-quarter.
  • 6 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2019 and 3 closed out, a net change of +3 holders.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2019 was Raymond James & Associates, an estimated $341K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q3 2019 was Sabby Management, an estimated $622K sold.

Based on aggregated 13F filings for Q3 2019.